Illumina to preview newest innovations in NGS and multiomic technologies at the American Society of Human Genetics Annual Meeting

New, groundbreaking technology delivers Illumina's most comprehensive genome yet; early results from Broad Clinical Labs demonstrate a highly simplified workflow, ultra-long phasing, high-resolution insights into complex genomic variation, and enhanced long-range information   Illumina and customers will also showcase new details on complete proteomics solution and latest data on Fluent single-cell technologySAN DIEGO, Oct. 31, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequ ...